Simone Saibeni

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.

Journal: Journal of Crohn's & colitis

Published: July 07, 2026

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.

Journal: Journal of Crohn's & colitis

Published: July 01, 2026

Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: June 05, 2026

Risk Factors for Inadequate Bowel Preparation Before Colonoscopy in Patients with Ulcerative Colitis in Clinical and Endoscopic Remission: A Multicenter Retrospective Cohort Study.

Journal: Diagnostics (Basel, Switzerland)

Published: January 04, 2026

Learning curve in intestinal ultrasound: advancing from basic skills to advanced competencies-insights from the IUS IG-IBD Master program.

Journal: Journal of Crohn's & colitis

Published: December 23, 2025

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 07, 2025

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 07, 2025

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 07, 2025

Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey.

Journal: European journal of gastroenterology & hepatology

Published: June 18, 2025

A multicenter study on bowel preparation in inflammatory bowel disease patients: comparison between 1L-PEG-ASC and 2L-PEG regimens in an outpatient setting.

Journal: European journal of gastroenterology & hepatology

Published: June 05, 2025

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.

Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study.

Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study.

Risk Factors for Inadequate Bowel Preparation Before Colonoscopy in Patients with Ulcerative Colitis in Clinical and Endoscopic Remission: A Multicenter Retrospective Cohort Study.

Risk Factors for Inadequate Bowel Preparation Before Colonoscopy in Patients with Ulcerative Colitis in Clinical and Endoscopic Remission: A Multicenter Retrospective Cohort Study.

Learning curve in intestinal ultrasound: advancing from basic skills to advanced competencies-insights from the IUS IG-IBD Master program.

Learning curve in intestinal ultrasound: advancing from basic skills to advanced competencies-insights from the IUS IG-IBD Master program.

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis.

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis.

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis.

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis.

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis.

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis.

Is it time to introduce health coaching in inflammatory bowel disease management?

Is it time to introduce health coaching in inflammatory bowel disease management?

Upper Gastrointestinal Crohn's Disease: Shedding Light on the Obscure L4 Classification Meaning.

Upper Gastrointestinal Crohn's Disease: Shedding Light on the Obscure L4 Classification Meaning.

Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey.

Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey.

A multicenter study on bowel preparation in inflammatory bowel disease patients: comparison between 1L-PEG-ASC and 2L-PEG regimens in an outpatient setting.

A multicenter study on bowel preparation in inflammatory bowel disease patients: comparison between 1L-PEG-ASC and 2L-PEG regimens in an outpatient setting.